#cannabispolitics - "Mace was less positive, saying, “I don't have a lot of hope anything will happen this year.”

If anything will happen, she said it would need to be done before June.

“After June, it will be about the presidential election,” Mace said. If that doesn't happen, she expects it could be another two years.

But, she noted, President Biden could use it as a boost for his reelection. In other words, he could employ rescheduling as a way to get more votes.

On a positive note, Mace mentioned that the Biden administration has reached out to her office, which she was pleasantly surprised about."

#psychedelics - "Under the influence of MDMA, the drug also known as ecstasy, Joe and his wife were able to reach new understanding, voicing their true feelings and listening to the other. Now, a few times a year, the New Mexico couple calls a babysitter, goes out to dinner, and spends the night in a fancy hotel room where they take the drug and discuss issues in their almost decade-long marriage, ranging from chores to parenting to sex. “Taking on those bigger issues is just not a big deal now,” Joe says."

#psychedelicslaw - "In a complaint filed Monday, Reunion said the timing of communications with the U.S. Patent and Trademark Office makes it clear that Mindset Pharma Inc. copied a Reunion scientist's work and is attempting to pass it off as its own.

The complaint centers around a novel serotonergic psychedelic compound that Reunion labeled RE-104, for which it was issued U.S. Patent No. 11,292,765. According to the complaint, the compound meant to treat mental health conditions was developed by Reunion's chief scientific officer, Nathan Bryson, in mid-2020.

Bryson filed provisional patent applications for the compound in November 2020 and June 2021, and the PTO issued the patent on April 5, 2022, according to the complaint, giving Reunion full rights to the compound."